<DOC>
	<DOC>NCT01469052</DOC>
	<brief_summary>The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.</brief_summary>
	<brief_title>First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients with cytologically or histologically confirmed solid tumor(s) and with at least one measurable disease site Patients with adequate bone marrow, liver and kidney function Patients with life expectancy of at least 12 weeks Patients who have received chemotherapy, immunotherapy, radiotherapy or any investigational agent within 4 weeks of study entry Patients with have had a major surgical procedure within 4 weeks of study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>